Literature DB >> 15701867

Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth.

Ofra Benny1, Maayan Duvshani-Eshet, Theresa Cargioli, Lorenzo Bello, Andreas Bikfalvi, Rona S Carroll, Marcelle Machluf.   

Abstract

PURPOSE: There is an urgent need for modalities that can localize and prolong the administration of the antitumor agents, particularly antiangiogenic, to achieve long-term tumor inhibition. However, one of the major obstacles is designing a device in which the biological activity of sensitive endogenous inhibitors is retained. We have designed a biodegradable polymeric device, which provides a unique and practical means of localizing and continuously delivering hemopexin (PEX) or platelet factor 4 fragment (PF-4/CTF) at the tumor site while maintaining their biological activity. The potential and efficacy of this system is shown in vitro and in vivo in a human glioma mouse model. EXPERIMENTAL
DESIGN: Polymeric microspheres made of poly(lactic-co-glycolic acid) (PLGA) were loaded with very low amounts of PEX and PF-4/CTF. The release profiles of these factors from PLGA and their biological activity were confirmed in vitro using proliferation assays done on endothelial and tumor cells. Tumor inhibition using this system was studied in nude mice bearing a human s.c. glioma.
RESULTS: PEX and PF-4/CTF released in vitro from PLGA microspheres were biologically active and significantly inhibited the proliferation of human umbilical vein endothelial cells, bovine capillary endothelial cells, and U87-MG cells. A single local s.c. injection of PLGA microspheres loaded with low amounts of PEX or PF-4/CTF resulted in an 88% and 95% reduction in glioma tumor volume 30 days post-treatment. Immunohistochemical analysis of the treated tumors showed a marked decrease in tumor vessel density compared with untreated tumors.
CONCLUSION: Our findings show that polymeric microspheres are a very promising approach to locally and efficiently deliver endogenous inhibitors to the tumor site leading to a significant inhibition of the tumor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701867

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  Biomaterials for the central nervous system.

Authors:  Yinghui Zhong; Ravi V Bellamkonda
Journal:  J R Soc Interface       Date:  2008-09-06       Impact factor: 4.118

2.  Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis.

Authors:  Oksan Karal-Yilmaz; Abdulkadir Ozkan; Emel Akgun; Manolya Kukut; Kemal Baysal; Timucin Avsar; Turker Kilic
Journal:  J Mater Sci Mater Med       Date:  2012-10-10       Impact factor: 3.896

Review 3.  Localized targeted antiangiogenic drug delivery for glioblastoma.

Authors:  Gregory D Arnone; Abhiraj D Bhimani; Tania Aguilar; Ankit I Mehta
Journal:  J Neurooncol       Date:  2018-01-11       Impact factor: 4.130

4.  Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

Authors:  Ruman Rahman; Stuart Smith; Cheryl Rahman; Richard Grundy
Journal:  J Oncol       Date:  2010-04-11       Impact factor: 4.375

5.  Nano to micro delivery systems: targeting angiogenesis in brain tumors.

Authors:  Ariel Gilert; Marcelle Machluf
Journal:  J Angiogenes Res       Date:  2010-10-08

Review 6.  Novel technologies for antiangiogenic drug delivery in the brain.

Authors:  Ofra Benny; Pouya Pakneshan
Journal:  Cell Adh Migr       Date:  2009-04-06       Impact factor: 3.405

Review 7.  Current advances in research and clinical applications of PLGA-based nanotechnology.

Authors:  Jian-Ming Lü; Xinwen Wang; Christian Marin-Muller; Hao Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2009-05       Impact factor: 5.225

8.  Validation of weak biological effects by round robin experiments: cytotoxicity/biocompatibility of SiO2 and polymer nanoparticles in HepG2 cells.

Authors:  Lisa Landgraf; Daniel Nordmeyer; Peter Schmiel; Qi Gao; Sandra Ritz; Julia S Gebauer; Stefan Graß; Silvia Diabaté; Lennart Treuel; Christina Graf; Eckart Rühl; Katharina Landfester; Volker Mailänder; Carsten Weiss; Reinhard Zellner; Ingrid Hilger
Journal:  Sci Rep       Date:  2017-06-28       Impact factor: 4.379

9.  Ultrasound-Mediated Mesenchymal Stem Cells Transfection as a Targeted Cancer Therapy Platform.

Authors:  Tom Haber; Limor Baruch; Marcelle Machluf
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

10.  Encapsulated Carbenoxolone Reduces Lung Metastases.

Authors:  Adi Karsch-Bluman; Shimrit Avraham; Miri Assayag; Ouri Schwob; Ofra Benny
Journal:  Cancers (Basel)       Date:  2019-09-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.